{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:08:56Z","timestamp":1771538936811,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T00:00:00Z","timestamp":1509667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/eye.2017.230","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T14:55:33Z","timestamp":1509720933000},"page":"537-545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result"],"prefix":"10.1038","volume":"32","author":[{"given":"P L","family":"Lip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Cikatricis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Sarmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Damato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Elsherbiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,3]]},"reference":[{"key":"BFeye2017230_CR1","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMcp1003934","volume":"363","author":"TY Wong","year":"2010","unstructured":"Wong TY, Scott IU . Retinal-vein occlusion. N Eng J Med 2010; 363: 2135\u20132144.","journal-title":"N Eng J Med"},{"issue":"4","key":"BFeye2017230_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archopht.126.4.513","volume":"126","author":"R Klein","year":"2008","unstructured":"Klein R, Moss SE, Meuer SM, Klein BE . The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126 (4): 513\u2013518.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"BFeye2017230_CR3","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ophtha.2012.06.037","volume":"119","author":"DL Epstein","year":"2012","unstructured":"Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119 (12): 2587\u20132591.","journal-title":"Ophthalmology"},{"issue":"4","key":"BFeye2017230_CR4","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119 (4): 802\u2013809.","journal-title":"Ophthalmology"},{"issue":"7","key":"BFeye2017230_CR5","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","volume":"121","author":"JS Heier","year":"2014","unstructured":"Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121 (7): 1414\u20131420.","journal-title":"Ophthalmology"},{"issue":"12","key":"BFeye2017230_CR6","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118 (12): 2453\u20132460.","journal-title":"Ophthalmology"},{"issue":"6","key":"BFeye2017230_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (6): 1124\u20131133.","journal-title":"Ophthalmology"},{"issue":"8","key":"BFeye2017230_CR8","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118 (8): 1594\u20131602.","journal-title":"Ophthalmology"},{"key":"BFeye2017230_CR9","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2147\/OPTH.S89147","volume":"9","author":"PL Lip","year":"2015","unstructured":"Lip PL, Malick H, Damer K, Elsherbiny S, Darrad KM, Mushtaq B et al. One year outcome of bevacizumab therapy for chronic macular oedema in branch and central retinal vein occlusions in the real world clinical practice in the United Kingdom. Clin Ophthalmol 2015; 9: 1779\u20131784.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"BFeye2017230_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/IAE.0b013e31804a7af2","volume":"27","author":"Y Matsumoto","year":"2007","unstructured":"Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA . Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007; 27 (4): 426\u2013431.","journal-title":"Retina"},{"key":"BFeye2017230_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/OPTH.S75842","volume":"9","author":"MA Singer","year":"2015","unstructured":"Singer MA, Tan CS, Suprapaneni K, Sadda S . Targeted photocoagulation of peripheral ischaemia to treat rebound edema. Clin Ophthal 2015; 9: 337\u2013341.","journal-title":"Clin Ophthal"},{"issue":"7","key":"BFeye2017230_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0b013e318242b838","volume":"32","author":"MA Singer","year":"2012","unstructured":"Singer MA, Bell DJ, Woods P, Pollard J, Boord T, Herro A et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina 2012; 32 (7): 1289\u20131294.","journal-title":"Retina"},{"key":"BFeye2017230_CR13","first-page":"1057","volume":"8","author":"RK Maturi","year":"2014","unstructured":"Maturi RK, Chen V, Raghinaru D, Bleau L, Stewart MW . A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol 2014; 8: 1057\u20131064.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"BFeye2017230_CR14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ . Novel method for analyzing Snellen visual acuity measurements. Retina 2010; 30 (7): 1046\u20131050.","journal-title":"Retina"},{"key":"BFeye2017230_CR15","unstructured":"Snellen-logMAR Visual Acuity Calculator. Available from \n                    http:\/\/www.myvisiontest.com\/logmar.php\n                    \n                  ."},{"issue":"5","key":"BFeye2017230_CR16","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1167\/iovs.07-0273","volume":"49","author":"A Nehme","year":"2008","unstructured":"Nehme A, Edelman J . Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 2008; 49 (5): 2030\u20132038.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye2017230_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","volume":"120","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom B, Cree IA et al. Correlation of increased vascular endothelial growth factor with neovascularisation and permeability in ischaemic central retinal vein occlusion. Arch Ophthamol 2002; 120: 1644\u20131650.","journal-title":"Arch Ophthamol"},{"key":"BFeye2017230_CR18","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/j.1755-3768.2011.02292.x","volume":"90","author":"MJ Koss","year":"2012","unstructured":"Koss MJ, Pfister M, Rothweiler F, Michaelis M, Cinatl J, Schubert R et al. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthal 2012; 90: e98\u2013e103.","journal-title":"Acta Ophthal"},{"key":"BFeye2017230_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ajo.2005.03.003","volume":"140","author":"H Noma","year":"2005","unstructured":"Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256\u2013261.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2017230_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12886-015-0106-z","volume":"15","author":"P Dugel","year":"2015","unstructured":"Dugel P, Capone A, Singer M, Dreyer R, Dodwell D, Roth D et al. Two or more dexamethasone intravitreal implants in treatment-na\u00efve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 2015; 15: 118\u2013125.","journal-title":"BMC Ophthalmol"},{"key":"BFeye2017230_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/OPTH.S119373","volume":"11","author":"MA Singer","year":"2016","unstructured":"Singer MA, Jansen ME, Tyler L, Woods P, Ansari F, Jain U et al. Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. Clin Ophthalmol 2016; 11: 31\u201338.","journal-title":"Clin Ophthalmol"},{"key":"BFeye2017230_CR22","unstructured":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102 (10): 1425\u20131433."},{"issue":"1","key":"BFeye2017230_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IAE.0b013e3182641875","volume":"33","author":"RF Spaide","year":"2013","unstructured":"Spaide RF . Prospective study of peripheral panretinal photocoagulation of areas of nonperfusion in central retinal vein occlusion. Retina 2013; 33 (1): 56\u201362.","journal-title":"Retina"},{"issue":"7","key":"BFeye2017230_CR24","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I et al. Scatter photocoagulation does not reduce macular oedema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 2015; 122 (7): 1426\u20131437.","journal-title":"Ophthalmology"},{"issue":"2","key":"BFeye2017230_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123 (2): 330\u2013336.","journal-title":"Ophthalmology"},{"issue":"6","key":"BFeye2017230_CR26","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2016.02.030","volume":"123","author":"R Tadayoni","year":"2016","unstructured":"Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016; 123 (6): 1332\u20131334.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2017230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2017230","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/eye.2017.230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/eye2017230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:31:34Z","timestamp":1684431094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2017230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["BFeye2017230"],"URL":"https:\/\/doi.org\/10.1038\/eye.2017.230","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,3]]},"assertion":[{"value":"4 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PLL is a speaker for Norvatis. PC is a travel-sponsorship recipient from Allergan and Norvatis. EMD is a speaker for Norvatis. AM is an Advisory Board Member of and speaker for Alimera Sciences. SE is an Advisory Board Member of and speaker for Alimera Science, Bayer, Novartis, and Alcon. YY is an Advisory Board Member of and speaker for Alimera Science, Allergan, Bayer, Novartis, Pfizer, and Thrombogenics. BM is an Advisory Board Member of and speaker for Alimera Science, Allergan, Bayer, Novartis, and ORAYA therapeutics. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}